

CNMV
Markets Directorate General
C/ Edison núm. 4
28006 Madrid

Madrid, October 29, 2026

In accordance with the provisions of article 227 of the Spanish Securities Markets and Investment Services Act (*Ley de los Mercados de Valores y de los Servicios de Inversión*), approved by Law 6/2023, of 17 March, and concordant provisions, is hereby reported the following:

OTHER RELEVANT INFORMATION

The Board of Directors of Pharma Mar, S.A. (the “**Company**”), at its meeting held today, took note of the personal decision of Ms. María Luisa de Francia Caballero, Chief Financial Officer of the Pharma Mar Group, to retire effective 31 December 2026, following a long and distinguished professional career within the Group.

As part of the planned succession process designed to ensure continuity in the Company’s finance function, the Board of Directors, upon the proposal of the Appointments, Compensation and Sustainability Committee, has resolved to appoint Ms. Elena Calleja Crespo as Chief Financial Officer of the Pharma Mar Group, a position she will assume effective 1 January 2027.

Ms. Elena Calleja Crespo holds a degree in Economics from the Complutense University of Madrid, specialising in Monetary Economics and the Public Sector, and a Master’s Degree in Corporate Tax Advisory from ICADE. She has more than thirty-five years of professional experience in the financial sector. During her tenure at Pharma Mar, she has held various positions within the finance area and, for the past eighteen years, has served as Chief Financial Officer of the Oncology Business Unit.

The Company wishes to express its recognition and appreciation to Ms. María Luisa de Francia Caballero for her exemplary professional career, dedication and commitment throughout her thirty-nine years with the Pharma Mar Group, as well as for her valuable contribution to the Group’s development, growth and strengthening during that period. The Company also wishes Ms. Elena Calleja Crespo every success in the performance of her new responsibilities.